ArticleFrontiers in medicine2022
Protective effects of silver nanoparticles in isoproterenol-induced myocardial infarction in rats.
Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Mechanisms of Cardiovascular Toxicity Induced by Silver Nanoparticles: A Systematic Review of Preclinical Evidence.Cardiovascular toxicology · 2026Pooled it
- The biomedical application of inorganic metal nanoparticles in aging and aging-associated diseases.Journal of advanced research · 2025Pooled it
- Acute radiation-induced changes in the submandibular salivary gland and possible radioprotective role of silver nanoparticles: a histological, immunohistochemical, and ultrastructural study.Anatomy & cell biology · 2026Article
- The application of nanoparticles green-formulated by Lycium barbarum leaf aqueous extract in the treatment of myocardial infarction.Discover nano · 2026Article
- Exploring the Cardioprotective Potential ofCardiovascular & hematological disorders drug targets · 2026Article
- The future of cardiac repair: a review on cell-free nanotherapies for regenerative myocardial infarction.Drug delivery and translational research · 2025Review
- Antioxidant property of Silver Nanoparticles Loaded with Alcoholic Extraction of Lycium Shawii.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Advances in Nanoparticles in the Prevention and Treatment of Myocardial Infarction.Molecules (Basel, Switzerland) · 2024Review
- Metal-Based Nanoparticles for Cardiovascular Diseases.International journal of molecular sciences · 2024Review
- Water Extracts ofTheScientificWorldJournal · 2024Article
- Therapeutic potential of silver nanoparticles fromFrontiers in bioengineering and biotechnology · 2024Article
- Metallomics in pulmonary arterial hypertension patients.Pulmonary circulation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Silver nanoparticles (AgNPs) are widely used in the medical field, including cardiovascular. However, limited research has investigated the effect of AgNPs on the protection of myocardial infarction (MI). Objectives: Isoproterenol (Iso)-induced MI and the cardiac protection offered by AgNPs were investigated in the present study. Additionally, we characterized the profile of Ag in the form of nanoparticles. Methods: Twenty-four male Wistar rats were randomly divided into four groups as follows: normal, Iso, Iso + AgNO Results: The silver was confirmed in the form of nanoparticles by its size at intervals of 8.72-37.84 nm. Both AgNO Conclusion: These results suggested that AgNPs have more superior cardioprotective effect compared with AgNO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.